Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period (WBB)

Primary objective is to characterize the relative bioavailability and kinetic profile of wild blueberry polyphenols over 24-hours period.

Secondary objective is to examine the relationship between bioavailability and kinetic profile of wild blueberry polyphenols on markers of chronic diseases.

Study Overview

Detailed Description

This study is a randomized, single blinded, 2-arm, within-subjects, placebo-controlled design utilizing a multiple sampling, repeated measures paradigm to characterize the bioavailability and kinetic profile of wild blueberry polyphenols.

A planned sample size of 12 will be enrolled into the study. This study will require one initial screening visit, one pre-study visit, and 2 study visits. This study will take approximately 3-4 weeks per subject to complete.

The initial screening visit will provide subject with the informed consent document and determine subject eligibility through anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey relate to general eating, health, and exercise habits.

If willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend day) will be instructed at the Screening Visit and collected at the Pre-study visit to assess subjects' baseline dietary intake pattern. Subjects will be instructed to follow a strictly limited polyphenolic diet for 7 days prior to the study and throughout their participation time, while maintaining their usual diet pattern and physical activity, with counseling by staff investigator and/or Registered Dietitian. A dinner meal will be provided the day before the study visit to control the second meal effect from the food and beverage intake of the night before the study visit.

Subject will arrive at the center in a fasted state for at least 10 hours, well hydrated and rested. Each study visit will require blood draws throughout the visit. After evaluation of subject's health status (via anthropometric, vital sign and blood glucose measurements and in-person interview), a registered nurse will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw in the fasting state. Subjects will be randomized to receive a placebo or wild blueberry beverage treatment based on randomized treatment sequences at 2 study visits along with 3 standard meals (breakfast, lunch and dinner). The sequences of receiving the beverage treatments at each visit will be randomly assigned to one of two of following sequences: placebo-wild blueberry or wild blueberry-placebo.

Each study visit will involve with blood samples collection at time points 0 (fasting), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hour (h) for assessment of change in plasma metabolites of wild blueberry polyphenols and influence of metabolic and inflammation markers. Also, urine samples will be collected prior to the study treatment as a baseline and all voids over 6 time periods, 0 to 2 h, 2 to 4 h, 4 to 6 h, 6 to 8 h, 8 to 10h and 10 to 24 h during each study visit to assess wild blueberry polyphenolic metabolites.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60616
        • Clinical Nutrition Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 20-45 years of age
  • Body Mass Index (BMI) range from 25 to 33 kg/m2
  • Nonsmoker
  • No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease
  • Not taking any medications that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, dietary supplements, etc…
  • Able to provide informed consent
  • Able to comply and perform the procedures requested by the protocol
  • Weight stable: not gained or lost weight +/- 5 kg in previous 3 months

Exclusion Criteria:

  • Men and women who smoke
  • Past smokers: abstinence for minimum 2 years
  • Men and women with known or suspected food intolerance, allergies or hypersensitivity
  • Men and women known to have/diagnosed with diabetes mellitus
  • Men and women who have fasting blood glucose concentrations > 110mg/dL
  • Men and women who have uncontrolled blood pressure >120 mmHg/80 mmHg
  • Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries, etc...
  • Men and women with cancer other than non-melanoma skin cancer in previous 5 years
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study
  • Women who are lactating
  • Taking medication or dietary supplements that may interfere with the outcomes of the study; e.g., antioxidant supplement, anti-inflammation, lipid lowering medication, blood pressure lowering medication, etc... Subjects may choose to go off dietary supplements (requires 30 days washout); e.g., fish oil, probiotics, etc...
  • Men and women who have donated blood within 3 months of the Screening Visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months.
  • Men and women who are vegans
  • Substance (alcohol or drug) abuse within the last 2 years
  • Excessive coffee and tea consumers (> 4 cups/d) and berry consumers (>2 cups fresh/day
  • Men and women who do excessive exercise regularly or athlete
  • Unstable weight: gained or lost weight +/- 5 kg in previous 3 months
  • Women who are taking unstable dose and brand of hormonal contraceptives and/or stable dose and brand less than 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Placebo Comparator
Placebo Beverage
Other Names:
  • Placebo
Active Comparator: Wild Bluberries
Active Comparator
Wild Blueberry Beverage
Other Names:
  • Wild Blueberries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in plasma and urine polyphenol metabolite concentrations over 24 hours after wild blueberry consumption with a high carbohydrate and high fat meal.
Time Frame: 24 hours
To assess the kinetic profile and bioavailability of wild blueberry polyphenols when consume with a meal
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in metabolic and inflammation markers over 24 hours after wild blueberry consumption with a high carbohydrate and high fat meal.
Time Frame: 24 hours
The influence of wild blueberry consumption on metabolic and inflammation markers
24 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in oxidative stress markers over 24 hours after wild blueberry consumption with a high carbohydrate and high fat meal
Time Frame: 24 hours
The influence of wild blueberry consumption on oxidative stress markers
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Britt Burton-Freeman, Ph.D, MS, Illinois Institute of Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2014

Primary Completion (Actual)

January 8, 2015

Study Completion (Actual)

January 19, 2016

Study Registration Dates

First Submitted

June 17, 2014

First Submitted That Met QC Criteria

June 17, 2014

First Posted (Estimate)

June 19, 2014

Study Record Updates

Last Update Posted (Actual)

January 26, 2021

Last Update Submitted That Met QC Criteria

January 25, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Active Comparator

Subscribe